
    
      Through multicenter, open-label, randomised clinical trials, patients with resectable locally
      recurrent nasopharyngeal carcinoma are randomized into salvage surgery plus PD-1 treatment
      group and salvage surgery alone group. The efficacy and safety of patients between these two
      groups are compared.
    
  